Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Why the Mediterranean diet
WARNING Research Use Only (RUO): This product is a laboratory research material
You may have heard discussions around the use of GLP-1s to treat obesity, which has raised questions about whether health insurers should cover these medications for weight loss
While Wegovy, or semaglutide , primarily targets weight loss and diabetes, its role in conjunction with Vyvanse remains worthy of consideration, especially since no direct interactions between the medications have been identified
What is a GLP-1 program
Expert perspective Yoonhyuk Jang, MD, PhD, Postdoctoral Fellow in the Department of Immunology at Harvard Medical School, commented on the findings: This study suggests that semaglutide may be associated with a lower risk of adult-onset seizures or epilepsy in patients with type 2 diabetes, with the signal appearing more pronounced in late-onset cases among adults aged 60 years or older. He added: Given that age-associated brain insults are major contributors to adult-onset seizures and epilepsy, these findings may have implications beyond seizure risk alone and raise the possibility that semaglutide could also be relevant to broader brain health
